|
|
|
| Correlation between IL-6 Level and Neoadjuvant Chemotherapy in Triple-negative Breast Cancer |
| YU Jin-yu, LIU Da-lin, WANG Qi-peng, et al |
| Department of General Surgery, Shuyang County Mercy Hospital, Jiangsu Province 223600 |
|
|
|
Abstract 【Objective】To investigate the correlation between IL-6 levels and neoadjuvant chemotherapy for triple-negative breast cancer. 【Methods】A total of 120 patients with locally advanced breast invasive ductal carcinoma who underwent preoperative neoadjuvant chemotherapy in our hospital. The immunohistochemical results were all triple negative breast cancer. The level of IL-6 in peripheral blood before neoadjuvant chemotherapy was measured, and the correlation between IL-6 level and clinicopathological factors was analyzed. The correlation between chemotherapy and pathological complete remission (pCR) was analyzed. 【Results】The IL-6 level was (119.8±20.8) pg/mL. According to the median IL-6 level (118 pg/ml), the patients were divided into IL-6 low level group (60 cases) and IL-6 high level group (60 cases). There was no correlation of IL-6 level with age, menopausal status, tumor size and clinical stage in triple-negative breast cancer patients (P>0.05). IL-6 level was correlation with clinical stage and lymph node status of triple-negative breast cancer, the difference was statistically significant(P<0.05). The CR rate in the IL-6 high-level group was lower than that in the IL-6 low-level group, and the effective rate was lower than the IL-6 low-level group , the difference was statistically significant (P<0.05). A total of 25 patients had pCR after operation, and pCR was associated with clinical stage, IL-6 level, and tumor longest interval (P<0.05). Multivariate regression analysis showed clinical stage, IL-6 levels were independent factors affecting pCR. 【Conclusion】The level of IL-6 is associated with the efficacy of neoadjuvant chemotherapy for triple-negative breast cancer. The high-level IL-6 level of triple-negative breast cancer patients has a lower pCR rate.
|
|
Received: 10 October 2019
|
|
|
|
|
|
[1] GADI V K.Practical approach to triple-negative breast cancer[J].J Oncol Pract,2017,13(5):293-300.
[2] 李狄航,梁运升.乳腺癌分子分型及其临床治疗意义[J].中国基层医药,2018,25(17):2309-2312.
[3] WENG Y S, TSENG H Y, CHEN Y A, et al. MCT-1/miR-34a/IL-6/IL-6R signaling axis promotes EMT progression, cancer stemness and M2 macrophage polarization in triple-negative breast cancer[J].Mol Cancer,2019,18(1):42.
[4] 郑亚兵,俞洋,王晓稼.2017年St.Gallen国际乳腺癌会议内外科热点问题解读[J].健康研究,2017,37(4):361-365.
[5] JITARIU A A, CIMPEAN A M, RIBATTI D, et al. Triple negative breast cancer: the kiss of death[J].Oncotarget,2017,8(28):46652-46662.
[6] 胡香萍,刘贤明.血清IL-6、IL-8、IL-10与TNF-α在乳腺癌发生、转移及预后中的作用与临床意义[J].中国妇幼保健,2018,33(23):5375-5378.
[7] AHMAD N. IL-6 and IL-10 are associated with good prognosis in early stage invasive breast cancer patients[J].Cancer Immunol Immunother,2018,67(4):537-549.
[8] IBRAHIM S A, GADALLA R, ESLAM A, et al. Syndecan-1 is a novel molecular marker for triple negative inflammatory breast cancer and modulates the cancer stem cell phenotype via the IL-6/STAT3, Notch and EGFR signaling pathways[J].Molecular Cancer,2017, 16(1):57.
[9] 韩国晖.白细胞介素-6在三阴性乳腺癌患者血清中的表达[J].中华实验外科杂志,2018,35(7):1318-1320.
[10] 李曼曼,徐斌,邵营波, 等.不同雌激素受体状态下化疗周期数对乳腺癌新辅助化疗病理完全缓解率的影响[J].肿瘤防治研究,2017,44(1):38-41. |
|
|
|
2021, Vol. 38 
